Flu-Bu-Mel Conditioning Regimen for Myeloid Disease
Status:
Active, not recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing
allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day
melphalan